Allogene Therapeutics (ALLO) Change in Account Payables (2019 - 2025)
Historic Change in Account Payables for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$1.1 million.
- Allogene Therapeutics' Change in Account Payables rose 8516.67% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year decrease of 11406.44%. This contributed to the annual value of -$503000.0 for FY2024, which is 9329.51% up from last year.
- Latest data reveals that Allogene Therapeutics reported Change in Account Payables of -$1.1 million as of Q3 2025, which was up 8516.67% from -$422000.0 recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Change in Account Payables registered a high of $6.8 million during Q2 2024, and its lowest value of -$7.2 million during Q3 2024.
- Over the past 5 years, Allogene Therapeutics' median Change in Account Payables value was -$302000.0 (recorded in 2023), while the average stood at -$301789.5.
- Over the last 5 years, Allogene Therapeutics' Change in Account Payables had its largest YoY gain of 49770.11% in 2021, and its largest YoY loss of 66635.86% in 2021.
- Over the past 5 years, Allogene Therapeutics' Change in Account Payables (Quarter) stood at -$2.0 million in 2021, then soared by 243.74% to $2.9 million in 2022, then plummeted by 110.28% to -$302000.0 in 2023, then skyrocketed by 111.26% to $34000.0 in 2024, then crashed by 3252.94% to -$1.1 million in 2025.
- Its Change in Account Payables stands at -$1.1 million for Q3 2025, versus -$422000.0 for Q2 2025 and -$336000.0 for Q1 2025.